Trial Profile
Phase2 Study of OTS102 in Combination With Gemcitabine in Patients With Unresectable Advanced Biliary Tract Cancer and recurrent Biliary Tract Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Elpamotide (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Biliary cancer; Cholangiocarcinoma; Gallbladder cancer; Squamous cell cancer
- Focus Therapeutic Use
- 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 04 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.
- 03 Oct 2009 New trial record